This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hertz et al¹ call for action to decrease racial disparity in blood pressure (BP) control among treated hypertensive patients. The staff of the National Heart, Lung, and Blood Institute (NHLBI) had noted this disparity when the National Health and Nutrition Examination Survey (NHANES) 1999-2000 data were released and they developed a research initiative to improve hypertension control among treated African Americans.²

The 5-year, $18-million program "Interventions to Improve Hypertension Control in African Americans" consists of 5 randomized controlled trials testing several clinically feasible approaches to effect changes in medical care delivery, leading to an increase in the proportion of treated hypertensive African American patients whose BP is controlled to levels recommended by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) guidelines.³ The request for applications (RFA) was issued in September 2003; funding started in September 2004.² Nearly 3900 black patients are being enrolled . . . [Full Text of this Article]

AUTHOR INFORMATION
Paula T. Einhorn, MD; Jeffrey A. Cutler, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Racial Disparities in Hypertension Prevalence, Awareness, and Management
Robin P. Hertz, Alan N. Unger, Jeffrey A. Cornell, and Elijah Saunders
Arch Intern Med. 2005;165(18):2098-2104.
ABSTRACT | FULL TEXT  

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
Aram V. Chobanian, George L. Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph L. Izzo, Jr, Daniel W. Jones, Barry J. Materson, Suzanne Oparil, Jackson T. Wright, Jr, and Edward J. Roccella
JAMA. 2003;289(19):2560-2571.
ABSTRACT | FULL TEXT  

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2981-2997.
ABSTRACT | FULL TEXT  

Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2000;283(15):1967-1975.
ABSTRACT | FULL TEXT